What is HC Wainwright’s Estimate for SAGE FY2028 Earnings?

Sage Therapeutics, Inc. (NASDAQ:SAGE) – HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued on Wednesday, October 30th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will earn $0.50 per share for the year, down from their prior estimate of $0.56. HC Wainwright has a “Neutral” rating and a $14.00 price target on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.43) per share.

A number of other research firms have also commented on SAGE. Bank of America lowered their price target on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research report on Wednesday, October 9th. Scotiabank reduced their price objective on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a research note on Wednesday. The Goldman Sachs Group reduced their price objective on Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a research note on Friday, July 26th. JPMorgan Chase & Co. reduced their price objective on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $26.00 price objective (down previously from $52.00) on shares of Sage Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sage Therapeutics currently has a consensus rating of “Hold” and an average price target of $12.89.

Sage Therapeutics Trading Up 0.2 %

NASDAQ SAGE opened at $6.45 on Thursday. The firm has a market capitalization of $388.17 million, a P/E ratio of -0.77 and a beta of 0.91. The business has a fifty day simple moving average of $7.48 and a 200 day simple moving average of $9.97. Sage Therapeutics has a 12 month low of $5.84 and a 12 month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $10.80 million. Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The company’s quarterly revenue was up 337.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.81) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Sage Therapeutics by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after purchasing an additional 432,013 shares during the period. Bellevue Group AG boosted its stake in Sage Therapeutics by 27.1% in the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after purchasing an additional 952,193 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Sage Therapeutics by 69.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after purchasing an additional 333,805 shares during the period. Federated Hermes Inc. bought a new stake in shares of Sage Therapeutics during the 2nd quarter valued at about $7,281,000. Finally, Renaissance Technologies LLC boosted its position in shares of Sage Therapeutics by 1,476.6% during the 2nd quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock valued at $6,010,000 after acquiring an additional 518,296 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.